NasdaqGS:IMVTBiotechs
Will Immunovant’s (IMVT) US$550 Million Raise and Insider Sales Reframe Its Autoimmune Ambitions?
In recent months, Immunovant announced a US$550 million stock offering supported by controlling shareholder Roivant Sciences and reported insider share sales by its Chief Technology Officer to cover tax obligations on vested restricted stock units.
Analyst upgrades and reiterations have drawn attention to Immunovant’s autoimmune pipeline, with particular focus on the potential of its Graves’ disease candidate IMVT-1402.
Next, we’ll examine how this substantial capital raise to support...